Format

Send to

Choose Destination
Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8.

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Collaborators (372)

Arias P, Ulla MR, Alvarisqueta A, Maffei L, Fretes JO, De Lapertosa SG, Visco V, Sposetti G, Farias J, Farias EF, Cantero MC, Feldman R, Ridruejo MC, Calella P, Zaidman C, Stranks S, Jeffries W, Mah PM, Macissac R, Nankervis A, Topliss D, Soldatos G, Simpson R, Gerstman M, Colquhoun D, De Looze F, Moses R, Suranyi M, Hocking S, Packham D, Cooke D, Kostner K, Weber E, Vercammen C, Van Gaal L, Tits J, Vandemeulebroecke E, Keymeulen B, Mathieu C, Aggarwal N, Dattani D, Blouin F, Dumas R, Henein S, Ma P, Najarali A, Omahony M, Pella T, Rodger W, Shu D, Woo V, Zidel B, Pliamm L, Ramjattan B, Akhras R, Belle-Isle J, Ross S, Velasquez J, Orozco L, Burbano A, Andresova A, Komrskova M, Mucha C, Brychta T, Bartaskova D, Urbanova R, Spousta T, Havelkova J, Sedlacek T, Kvapil M, Jakovlev Ü, Fogel V, Viitas L, Soots M, Lubi M, Past M, Krasnopejeva J, Alawi H, Busch K, Tyler K, Thron A, Jacob S, Forst T, Pfützner A, Rose L, Segiet T, Kosch C, Moelle A, Davies M, Bell P, Gibson M, Gnudi L, Game F, Wilding J, Atkin S, Sathyapalan T, Fisher M, Ramtoola S, Rajbhandari S, Okane M, Beke E, Poor F, Nagy K, Kocsis G, Oroszlan T, Faludi P, Gurzo M, Srikanta S, Dharmalingam M, Murugan B, Gandhi P, Sethi B, Aravind S, Ardhanareeshwaran S, Bhattacharyya A, Bantwal G, Viswanathan V, Kumar P, Saboo B, Mohan V, Deshpande N, Modi KK, Joshi S, Jain S, Kalya S, Krishnan A, Adhikari P, Kumar A, Yajnik C, John M, Yalamanchi S, Parikh K, Puthourath BK, Menon JC, Kumar S, Rodrigues L, Gupta JB, Agarwal P, Gupta SK, Mutha AA, Kale SD, Kulkarni RL, Bhatt S, Sharma K, Yogeesha KS, Tangaonkar A, Deshmukh V, Majumdar B, Veerappan R, Namjoshi D, Raz I, Weinstein J, Boehm IH, Vishlitzky V, Dadoun F, Shah RP, Hooi LS, Tan A, Bebakar WM, Mohamed M, Khir AS, Sukor N, Abdul Kadir K, Morales E, Zuñiga S, Alpizar M, Calvo C, Zamarripa R, Rosas J, Vargas A, Nieuwdorp M, Kose V, Peeters M, Kentgens S, Agous I, Rojas G, Van Kempen W, Hoogendijk J, Alhakim M, Gerdes V, Kaasjager K, Hovens M, Viergever PE, Smit CJ, Basart DC, Spiering W, Van Dijk-Okla MK, Imholz BP, Van Leendert RJ, Ten Wolde M, Smak Gregoor PJ, Scott R, Krebs J, Baker J, Singh J, Young C, Langslet G, Hoeye K, Hoivik HO, Kjaernli T, Elle S, Istad H, Risberg K, Tandberg A, Solnoer L, Sirnes PA, Derezinski T, Arciszewska M, Franek E, Szyprowska E, Sowinski D, Petryka R, Czakanska-Dec B, Pulka G, Jusiak K, Dabrowski M, Kubalski P, Wojciechowska M, Madej A, Pupek-Musialik D, Chazova I, Kondrashkina O, Ivleva A, Kuzin A, Filatov A, Gomova T, Khokhlov A, Vorobjev S, Mirolyubova O, Boldueva S, Ershova O, Ballyzek M, Smolenskaya O, Yakushin SS, Zateyshchikov D, Arkhipov M, Kuzmenko A, Maksimov I, Motylev I, Rafalskiy V, Strongin L, Treshkur T, Volkova N, Barbarash O, Raskina T, Bartosh L, Nikolskaya I, Shutemova E, Gurevich V, Burova N, Idrisova E, Andreev D, Bart B, Bokarev I, Gapon L, Gordeev I, Gratsiansky N, Zalevskaya A, Sayganov S, Solovyev O, Reshedko G, Shilkina N, Chizhov P, Shapovalova J, Sherenkov A, Reshetko O, Simanenkov V, Puig JG, Saban J, Pascual J, De Teresa L, Dominguez J, Delgado E, Calvo C, Vida M, Duran S, Tinahones F, Salas J, Gonzalez JM, Monreal M, Paz MA, Nubiola A, Alvarez P, Stenlöf K, Koskinen P, Lindholm CJ, Nilsson L, Mathiesen U, Blom KB, Tengmark BO, Larsson K, Jul-Nielsen H, Norrby A, Larin O, Panina S, Popik G, Kovalenko S, Voloshyna O, Tseluyko V, Gyrina O, Vizir V, Barna O, Dolzhenko M, Ignatenko G, Mostovoy Y, Korpachev V, Mankovskiy B, Vatutin M, Akpunonu B, Zerikly R, Baker C, Wine A, Kravitz A, Bartilucci D, Barzilay J, Breton C, Buse J, Cherlin R, Cobble M, Ellis C, Fink R, Forker A, Garcia R, Agarwal N, Hollander P, House A, Huynh M, Ingebretsen R, Jack D, Kirstein J, Lee F, Lorber D, McNeil D, Miers W, Murray A, Call R, Ong ST, Ovalle F, Pearlstein R, Piziak V, Pomposini D, Robertson D, Rosenstock J, Schubart U, Shah S, Stout R, Turner M, Wallace J, Chuck L, Weiss R, White J, Wynne A, Wysham C, Alderman M, Crump W, Pogue B, Silva A, Guthrie R, Lerman S, Madder R, Janosz KN, Weiss D, Kereiakes D, Graf RJ, Rassouli N, Muse D, Kalen V, Kersh R, Fernandez-Miro H, Dobrusin R, Johnson G, Bruce T.

Author information

1
The Royal North Shore Hospital and University of Sydney, Sydney, Australia.
2
Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK.
3
The George Institute for Global Health, The Royal Prince Alfred Hospital, and University of Sydney, Sydney, Australia.
4
Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
5
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
6
Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
7
Endocrinology Section, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
8
Washington State University, Spokane, WA, USA.
9
Janssen Research & Development, LLC, Raritan, NJ, USA.
10
Janssen Research & Development, Beerse, Belgium.

Abstract

AIMS:

To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic [dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist].

METHODS:

CANVAS is a double-blind, placebo-controlled study that randomized participants to canagliflozin 100 or 300 mg or placebo added to routine therapy. The present post hoc analysis assessed the efficacy and safety of canagliflozin 100 and 300 mg compared with placebo in subsets of patients from CANVAS who were taking background DPP-4 inhibitors or GLP-1 receptor agonists with or without other antihyperglycaemic agents at week 18.

RESULTS:

Of the 4330 patients in CANVAS, 316 were taking DPP-4 inhibitors and 95 were taking GLP-1 receptor agonists. At 18 weeks, canagliflozin 100 and 300 mg provided larger placebo-subtracted reductions in glycated haemoglobin (HbA1c) in patients taking DPP-4 inhibitors [-0.56% (95% confidence interval [CI]: -0.77, -0.35), and -0.75% (95% CI: -0.95, -0.54), respectively] and GLP-1 receptor agonists [-1.00% (95% CI: -1.35, -0.65), and -1.06% (95% CI: -1.43, -0.69), respectively]. Body weight and blood pressure (BP) reductions were seen with canagliflozin versus placebo in both subsets. Higher incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo. The incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo; nearly all events occurred in patients on background insulin or insulin secretagogues.

CONCLUSIONS:

In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition.

KEYWORDS:

canagliflozin; type 2 diabetes

PMID:
26450639
DOI:
10.1111/dom.12589
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center